Table 3.

Treatment administered (n=151) for COVID-19 based on disease severity

	Mild disease (no supplemental oxygen required)		Moderate or severe disease (supplemental oxygen or mechanical ventilation required, or both)		Disease severity unknown
	Allogeneic HSCT (n=86)	Autologous HSCT (n=69)	Allogeneic HSCT (n=77)	Autologous HSCT (n=44)	Allogeneic HSCT (n=21)	Autologous HSCT (n=21)
No medications reported	2 (2%)	0	2 (3%)	0	20 (95%)	20 (95%)
No treatment given	57 (66%)	44 (64%)	13 (17%)	8 (18%)	0	1 (5%)
COVID-19 convalescent plasma	2 (2%)	1 (1%)	9 (12%)	6 (14%)	1 (5%)	0
Remdesivir	2 (2%)	4 (6%)	22 (29%)	9 (20%)	1 (5%)	0
Tocilizumab	0	0	4 (5%)	3 (7%)	0	0
Hydroxychloroquine	4 (5%)	7 (10%)	18 (23%)	11 (25%)	0	0
Azithromycin	7 (8%)	3 (4%)	5 (6%)	1 (2%)	0	0
Lopinovir or ritonovir (Kaletra)	0	1 (1%)	0	0	0	0
Methylprednisolone	0	0	1 (1%)	1 (2%)	0	0
Oseltamivir	1 (1%)	0	3 (4%)	2 (5%)	0	0
Ribavirin	0	1 (1%)	0	0	0	0
DAS181	0	0	1 (1%)	0	0	0
Acyclovir or valacyclovir	7 (8%)	5 (7%)	7 (9%)	4 (9%)	0	0
Famciclovir	0	0	0	1 (2%)	0	0
Antibacterial agent	2 (2%)	7 (10%)	6 (8%)	9 (20%)	0	0
Other drug*	3 (3%)	1 (1%)	1 (1%)	0	0	0

Data are n (%). Treatments are not mutually exclusive and are as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). HSCT=haematopoietic stem cell transplantation.

^*Other drugs include albuterol, ascorbic acid, fluconazole, and ruxolitinib.